EUCTR2004-001969-17-IT进行中（未招募）不适用
A double-blind, placebo-controlled, parallel group study with an open label extension phase, to assess the efficacy, tolerability and safety of oral frovatriptan in the prevention of menstrually-related migraine (MRM) headaches in a 'difficult to treat' population.
VERNALIS DEVELOPMENT LIMITED0 个研究点目标入组 700 人开始时间: 2005年8月2日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 700
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
不适用
A double-blind, placebo-controlled, parallel group, proof of concept trial to assess the tolerabiltiy, safety and efficacy of rotigotine nasal spray for the acute treatment of 'off' symptoms in subjects with advanced-stage, idiopathic Parkinson's diseaseadvanced-stage, idiopathic Parkinson's diseaseMedDRA version: 8.1Level: LLTClassification code 10061536EUCTR2005-004290-19-ATSchwarz Biosciences GmbH100
进行中（未招募）
不适用
A double-blind, placebo-controlled, parallel group, proof of concept trial to assess the tolerabiltiy, safety and efficacy of rotigotine nasal spray for the acute treatment of 'off' symptoms in subjects with advanced-stage, idiopathic Parkinson's diseaseadvanced-stage, idiopathic Parkinson's diseaseMedDRA version: 8.1Level: LLTClassification code 10061536EUCTR2005-004290-19-DESchwarz Biosciences GmbH100
进行中（未招募）
不适用
A double-blind, placebo-controlled, parallel group study, with an open-label extension phase, to assess the efficacy, tolerability and safety of oral frovatriptan in the prevention of menstrually-related migraine (MRM) headaches in a 'difficult to treat' population. - MRM02Menstrually Related Migraine (MRM)EUCTR2004-001969-17-SEVernalis Development Limited550
进行中（未招募）
不适用
A double-blind, placebo-controlled, parallel group study, with an open-label extension phase, to assess the efficacy, tolerability and safety of oral frovatriptan in the prevention of menstrually-related migraine (MRM) headaches in a ‘difficult to treat’ population - MRM02Menstrually-Related Migraine (MRM)EUCTR2004-001969-17-DEVernalis Development Limited550
进行中（未招募）
1 期
A double-blind, placebo-controlled, parallel group study, with an open-label extension phase, to assess the efficacy, tolerability and safety of oral frovatriptan in the prevention of menstrually-related migraine (MRM) headaches in a ‘difficult to treat’ population - MRM02Menstrually-Related Migraine (MRM)EUCTR2004-001969-17-GBVernalis Development Limited550